Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two Phase I Studies, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative.

Next Previous
Trial Profile

Two Phase I Studies, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RG 4733 (Primary)
  • Indications Advanced breast cancer; Brain metastases; Cancer metastases; Lung cancer; Malignant melanoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

  • 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 14 Jan 2013 Planned end date changed from 1 Mar 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
  • 15 Oct 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top